Mar 20 |
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
|
Mar 18 |
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
|
Feb 28 |
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
|
Feb 14 |
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
|
Feb 1 |
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
|
Jan 27 |
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
|
Jan 24 |
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
|
Jan 23 |
Silo Pharma files for $25M mixed securities shelf
|
Jan 12 |
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
|
Jan 7 |
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
|